/VOR
VOR Stock - Vor Biopharma Inc.
Healthcare|BiotechnologyNASDAQ
$12.41-3.05%
$0.39 (-3.05%) • Dec 19
52
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.0
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.37
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+367.4%upside
Target: $58.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VOR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$12.29 – $12.53
TARGET (TP)$58.00
STOP LOSS$11.42
RISK/REWARD1:46.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.08
52W High$65.80
52W Low$2.62
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | $-3,492,000 | $-8,960,000 | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-121,185,000 | $-126,036,000 | $-93,418,000 | $-69,018,000 | $-43,366,000 |
| Net Income | $-116,914,000 | $-117,863,000 | $-92,094,000 | $-68,899,000 | $-43,337,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $-34.00 | $-35.00 | $-46.60 | $-37.80 | $-26.60 |
Company Overview
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
5
71%
Hold / Neutral
2
29%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
5 Bullish2 Neutral/Bearish
Price Targets
$28
Average Target
↑ 127.9% Upside
Now
$3
Low
$28
Average
$64
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 17th 2025 | TD Cowen | Initiation | Buy | - |
| December 9th 2025 | JP Morgan | Initiation | Overweight | $43 |
| November 25th 2025 | Wedbush | Resumed | Neutral | $9 |
| October 15th 2025 | Robert W. Baird | Upgrade | Outperform | $64 |
| September 24th 2025 | Stifel | Upgrade | Buy | $55 |
| June 30th 2025 | H.C. Wainwright | Upgrade | Buy | $3 |
| July 26th 2022 | Wedbush | Initiation | Outperform | $18 |
| April 27th 2022 | Goldman | Initiation | Neutral | $6 |
Earnings History & Surprises
VORBeat Rate
28%
Last 18 quarters
Avg Surprise
-18.5%
EPS vs Estimate
Beats / Misses
5/11
2 met exactly
Latest EPS
$-3.33
Q4 2025
EPS Surprise History
Q1 24
+20.4%
$-0.39vs$-0.49
Q2 24
-21.6%
$-0.45vs$-0.37
Q3 24
0.0%
$-0.41vs$-0.41
Q4 24
0.0%
$-0.40vs$-0.40
Q1 25
-29.4%
$-0.44vs$-0.34
Q2 25
-4.0%
$-0.26vs$-0.25
Q3 25
-282.5%
$-43.60vs$-11.40
Q4 25
-8.8%
$-3.33vs$-3.06
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-2.09 | — | — | — |
Q4 2025 | Nov 13, 2025 | $-3.06 | $-3.33 | -8.8% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-11.40 | $-43.60 | -282.5% | ✗ MISS |
Q2 2025 | May 14, 2025 | $-0.25 | $-0.26 | -4.0% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.34 | $-0.44 | -29.4% | ✗ MISS |
Q4 2024 | Nov 7, 2024 | $-0.40 | $-0.40 | 0.0% | = MET |
Q3 2024 | Aug 8, 2024 | $-0.41 | $-0.41 | 0.0% | = MET |
Q2 2024 | May 9, 2024 | $-0.37 | $-0.45 | -21.6% | ✗ MISS |
Q1 2024 | Mar 20, 2024 | $-0.49 | $-0.39 | +20.4% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.46 | $-0.49 | -6.5% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.42 | $-0.45 | -7.1% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.38 | $-0.43 | -13.2% | ✗ MISS |
Q1 2023 | Mar 23, 2023 | $-0.56 | $-0.53 | +5.4% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.60 | $-0.63 | -5.0% | ✗ MISS |
Q3 2022 | Aug 11, 2022 | $-0.67 | $-0.58 | +13.4% | ✓ BEAT |
Q2 2022 | May 12, 2022 | $-0.54 | $-0.61 | -13.0% | ✗ MISS |
Q1 2022 | Mar 14, 2022 | $-0.55 | $-0.49 | +10.9% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.58 | $-0.50 | +13.8% | ✓ BEAT |
Q3 2021 | Aug 9, 2021 | $-0.47 | $-0.50 | -6.4% | ✗ MISS |
Latest News
JP Morgan Maintains Overweight on Vor Biopharma, Lowers Price Target to $40
➖ NeutralBenzinga•Dec 19, 2025, 04:25 PM
TD Cowen Initiates Coverage On Vor Biopharma with Buy Rating
📈 PositiveBenzinga•Dec 17, 2025, 03:20 PM
Vor Bio shares are trading higher after the company announced a $150 million private placement.
📈 PositiveBenzinga•Dec 15, 2025, 05:38 PM
UPDATE: Vor Bio Announces $150M Private Placement To Sell 13,876,032 Shares Of Its Common Stock At A Price Of $10.81 Per Share To A Select Group Of Institutional And Accredited Healthcare Specialist Investors
➖ NeutralBenzinga•Dec 15, 2025, 01:52 PM
Vor Bio Announces $150M Private Placement Of Common Stock At $10.81/Shr
➖ NeutralBenzinga•Dec 15, 2025, 01:02 PM
Vor Biopharma shares are trading higher after JP Morgan initiated coverage on the stock with an Overweight rating and announced a $43 price target.
📈 PositiveBenzinga•Dec 9, 2025, 06:40 PM
Vor Bio spikes as J.P. Morgan starts at Overweight on lead asset
📈 PositiveSeeking Alpha•Dec 9, 2025, 03:53 PM
Market-Moving News for December 9th
➖ NeutralBenzinga•Dec 9, 2025, 12:21 PM•Also: ,
JP Morgan Initiates Coverage On Vor Biopharma with Overweight Rating, Announces Price Target of $43
📈 PositiveBenzinga•Dec 9, 2025, 12:09 PM
Wedbush Assumes Vor Biopharma at Neutral, Announces Price Target of $9
➖ NeutralBenzinga•Nov 25, 2025, 02:06 PM
HC Wainwright & Co. Maintains Buy on Vor Biopharma, Lowers Price Target to $32
➖ NeutralBenzinga•Nov 14, 2025, 12:51 PM
UPDATE: Vor Biopharma Q3 Adj. EPS $(3.33) Misses $(3.25) Estimate
📉 NegativeBenzinga•Nov 14, 2025, 04:27 AM
Vor Biopharma Q3 EPS $(121.63) May Not Compare To $(3.32) Estimate
📉 NegativeBenzinga•Nov 13, 2025, 09:33 PM
Vor Biopharma shares are trading lower after the company announced the pricing of a public offering of 10 million shares at $10 per share.
📉 NegativeBenzinga•Nov 11, 2025, 02:44 PM
Reported Earlier, Vor Bio Prices $100M Public Offering Of 10M Shares Of Common Stock At $10 Per Share
➖ NeutralBenzinga•Nov 11, 2025, 07:34 AM
Vor Biopharma slumps 26%, prices $100M equity at $10 per share
📉 NegativeSeeking Alpha•Nov 11, 2025, 06:44 AM
Vor Biopharma shares are trading lower after the company announced a $100 million offering.
📉 NegativeBenzinga•Nov 10, 2025, 09:18 PM
Vor Biopharma Launches $100M Common Stock Offering
➖ NeutralBenzinga•Nov 10, 2025, 09:03 PM
Reported Saturday, Vor Bio Phase 3 Study In China Shows Telitacicept Achieved Primary Endpoint Of Reducing Proteinuria In IgA Nephropathy With Significant Kidney Function Stabilization And Favorable Safety Profile
📈 PositiveBenzinga•Nov 10, 2025, 09:02 AM
Vor Bio Announced Telitacicept Achieved Primary Endpoint Of Reducing Proteinuria In Stage A Of Phase 3 Clinical Study For IgA Nephropathy In China; Statistically Significant Benefits Also Achieved Across All Key Secondary Endpoints
📈 PositiveBenzinga•Nov 8, 2025, 04:55 PM
Frequently Asked Questions about VOR
What is VOR's current stock price?
Vor Biopharma Inc. (VOR) is currently trading at $12.41 per share. The stock has moved -3.05% today.
What is the analyst price target for VOR?
The average analyst price target for VOR is $58.00, based on 1 analyst.
What sector is Vor Biopharma Inc. in?
Vor Biopharma Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VOR's market cap?
Vor Biopharma Inc. has a market capitalization of $0.09 billion, making it a small-cap company.
Does VOR pay dividends?
No, Vor Biopharma Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACTU
Actuate Therapeutics Inc
$6.98
Mkt Cap: $0.2B
ALEC
Alector, Inc.
$1.40
Mkt Cap: $0.1B
ANIX
Anixa Biosciences, Inc.
$3.30
Mkt Cap: $0.1B
APLT
Applied Therapeutics, Inc.
$0.13
Mkt Cap: $0.0B
FATE
Fate Therapeutics, Inc.
$1.05
Mkt Cap: $0.1B
FBRX
Forte Biosciences, Inc.
$29.69
Mkt Cap: $0.4B
MCRB
Seres Therapeutics, Inc.
$14.98
Mkt Cap: $0.1B
NKTX
Nkarta, Inc.
$1.79
Mkt Cap: $0.1B
PEPG
PepGen Inc.
$5.42
Mkt Cap: $0.4B
SPRO
Spero Therapeutics, Inc.
$2.32
Mkt Cap: $0.1B
Explore stocks similar to VOR for comparison